title: Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.
abstract: Monoclonal antibody preparations have demonstrated considerable clinical utility in the treatment of specific malignancies, as well as inflammatory and infectious diseases. Antibodies are conventionally delivered by passive administration, typically requiring costly large-scale laboratory development and production. Additional limitations include the necessity for repeat administrations, and the length of in vivo potency. Therefore, the development of methods to generate therapeutic antibodies and antibody like molecules in vivo, distinct from an active antigen-based immunization strategy, would have considerable clinical utility. In fact, adeno-associated viral (AAV) vector mediated delivery of immunoglobulin genes with subsequent generation of functional antibodies has recently been developed. As well, anon-viral vector mediated nucleic acid based delivery technology could permit the generation of therapeutic/prophylactic antibodies in vivo, obviating potential safety issues associated with viral vector based gene delivery. This delivery strategy has limitations as well, mainly due to very low in vivo production and expression of protein from the delivered gene. In the study reported here we have constructed an "enhanced and optimized" DNA plasmid technology to generate immunoglobulin heavy and light chains (i.e., Fab fragments) from an established neutralizing anti-HIV envelope glycoprotein monoclonal antibody (VRC01). This "enhanced" DNA (E-DNA) plasmid technology includes codon/RNA optimization, leader sequence utilization, as well as targeted potentiation of delivery and expression of the Fab immunoglobulin genes through use of "adaptive" in vivo electroporation. The results demonstrate that delivery by this method of a single administration of the optimized Fab expressing constructs resulted in generation of Fab molecules in mouse sera possessing high antigen specific binding and HIV neutralization activity for at least 7 d after injection, against diverse HIV isolates. Importantly, this delivery strategy resulted in a rapid increase (i.e., in as little as 48 h) in Fab levels when compared with protein-based immunization. The active generation of functional Fab molecules in vivo has important conceptual and practical advantages over conventional ex vivo generation, purification and passive delivery of biologically active antibodies. Further study of this technique for the rapid generation and delivery of immunoglobulin and immunoglobulin like molecules is highly relevant and timely.
authors.affiliation: Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA.
authors.forename: Kar
authors.initials: K
authors.lastname: Muthumani
authors.affiliation: Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA.
authors.forename: Seleeke
authors.initials: S
authors.lastname: Flingai
authors.affiliation: Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA.
authors.forename: Megan
authors.initials: M
authors.lastname: Wise
authors.affiliation: Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA.
authors.forename: Colleen
authors.initials: C
authors.lastname: Tingey
authors.affiliation: Department of Molecular Medicine; University of South Florida Morsani College of Medicine; Tampa, FL USA; Center for Molecular Delivery; University of South Florida; Tampa, FL USA.
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Ugen
authors.affiliation: Department of Pathology and Laboratory Medicine; University of Pennsylvania School of Medicine; Philadelphia, PA USA.
authors.forename: David B
authors.initials: DB
authors.lastname: Weiner
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D001691:Biological Therapy / Q000379:methods; D005260:Female; D015483:HIV Antibodies / Q000097:blood / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D015658:HIV Infections / Q000628:therapy; D015497:HIV-1 / Q000276:immunology*; D007140:Immunoglobulin Fab Fragments / Q000097:blood / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D054299:env Gene Products, Human Immunodeficiency Virus / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D007140:Immunoglobulin Fab Fragments; D011994:Recombinant Proteins; D054299:env Gene Products, Human Immunodeficiency Virus
keywords: DNA vaccine; HIV-1 neutralization; electroporation; mAbVRC01; monoclonal antibodies
references.citation: PLoS One. 2013;8(3):e57606
references.pmid: 23555563
references.citation: Drug Des Devel Ther. 2011;5:489-95
references.pmid: 22267918
references.citation: Vaccine. 2003 Jan 30;21(7-8):629-37
references.pmid: 12531331
references.citation: Blood. 2005 Sep 15;106(6):2059-68
references.pmid: 15928037
references.citation: Science. 2002 Aug 23;297(5585):1277-8; author reply 1277-8
references.pmid: 12194177
references.citation: Cancer Treat Rev. 2004 Apr;30(2):165-72
references.pmid: 15023434
references.citation: Front Biosci. 2007 Jan 01;12:2194-206
references.pmid: 17127456
references.citation: J Virol. 2008 Dec;82(23):11536-44
references.pmid: 18799583
references.citation: Gene Ther. 2011 Nov;18(11):1070-7
references.pmid: 21544096
references.citation: Sci Transl Med. 2013 May 29;5(187):187ra72
references.pmid: 23720583
references.citation: Sci Transl Med. 2012 Oct 10;4(155):155ra138
references.pmid: 23052295
references.citation: J Hematol Oncol. 2012 Nov 09;5:70
references.pmid: 23140144
references.citation: Nat Rev Genet. 2008 Oct;9(10):776-88
references.pmid: 18781156
references.citation: Nature. 2011 Nov 30;481(7379):81-4
references.pmid: 22139420
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
references.pmid: 12644702
references.citation: PLoS One. 2008;3(12):e3942
references.pmid: 19079604
references.citation: Drugs. 2008;68(4):487-506
references.pmid: 18318567
references.citation: AIDS. 2004 Feb 20;18(3):371-81
references.pmid: 15090788
references.citation: J Virol. 2011 Sep;85(17):8954-67
references.pmid: 21715490
references.citation: J Immunother. 2010 Jul-Aug;33(6):557-69
references.pmid: 20551840
references.citation: J Infect Dis. 2011 Jan 1;203(1):95-102
references.pmid: 21148501
references.citation: Mol Ther. 2010 Aug;18(8):1568-76
references.pmid: 20551910
references.citation: Expert Opin Biol Ther. 2011 Nov;11(11):1455-67
references.pmid: 21831008
references.citation: Scand J Immunol. 2001 Jul-Aug;54(1-2):39-44
references.pmid: 11439146
references.citation: Nat Rev Immunol. 2009 Oct;9(10):717-28
references.pmid: 19859066
references.citation: J Virol. 2009 May;83(9):4624-30
references.pmid: 19211745
references.citation: J Virol. 2012 Oct;86(20):11231-41
references.pmid: 22875963
references.citation: Science. 2010 Aug 13;329(5993):770-3
references.pmid: 20705840
references.citation: Mol Ther. 2010 Sep;18(9):1714-23
references.pmid: 20571540
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6895-906
references.pmid: 18980984
references.citation: J Immunol. 2011 Sep 15;187(6):2932-43
references.pmid: 21856939
references.citation: Clin Cancer Res. 2010 Feb 1;16(3):888-97
references.pmid: 20086002
references.citation: Nature. 2006 May 11;441(7090):161
references.pmid: 16688158
references.citation: N Engl J Med. 2007 Jul 5;357(1):39-51
references.pmid: 17611206
references.citation: Nat Med. 2009 Aug;15(8):901-6
references.pmid: 19448633
references.citation: Nature. 2003 Mar 20;422(6929):307-12
references.pmid: 12646921
references.citation: Curr Opin Chem Biol. 2010 Aug;14(4):529-37
references.pmid: 20643572
references.citation: Nat Rev Drug Discov. 2011 Feb;10(2):101-11
references.pmid: 21283105
references.citation: Nat Rev Immunol. 2010 May;10(5):301-16
references.pmid: 20414204
references.citation: Cancer Sci. 2009 Jul;100(7):1243-7
references.pmid: 19432892
references.citation: Science. 2008 Jul 25;321(5888):530-2
references.pmid: 18653883
references.citation: PLoS Negl Trop Dis. 2011 Jan 11;5(1):e928
references.pmid: 21264351
references.citation: N Engl J Med. 2011 May 19;364(20):1897-908
references.pmid: 21526923
references.citation: J Immunol. 2005 Jul 1;175(1):112-23
references.pmid: 15972637
references.citation: J Virol. 2007 Jun;81(12):6187-96
references.pmid: 17409164
references.citation: Science. 2010 Aug 13;329(5993):811-7
references.pmid: 20616231
references.citation: Mol Ther. 2012 Mar;20(3):669-78
references.pmid: 21952169
references.citation: Curr Pharm Biotechnol. 2011 Feb 1;12(2):268-74
references.pmid: 21050165
references.citation: Toxicon. 2010 Aug 1;56(1):75-85
references.pmid: 20338189
references.citation: Cancer Immun. 2013;13:5
references.pmid: 23390376
references.citation: Mol Ther. 2004 Mar;9(3):328-36
references.pmid: 15006599
references.citation: Science. 2010 Aug 13;329(5993):856-61
references.pmid: 20616233
references.citation: Mol Ther. 2007 Feb;15(2):411-21
references.pmid: 17235321
references.citation: Clin Dev Immunol. 2010;2010:697158
references.pmid: 20936120
references.citation: J Virol. 2011 Mar;85(6):2851-8
references.pmid: 21209108